Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer

Clinical Epigenetics

Table 1 CfDNA methylation-based liquid biopsy for LC

Purpose	Genes	Cases	Controls	Sensitivity/specificity	Samples	Methods	References
Diagnosis	SHOX2	208	175	60.0/90.0%	Plasma	qPCR	[42]
Diagnosis	RASSF1A/RARB	60	32	87.0/75.0%	Plasma	qMSP	[43]
Diagnosis	B3GAT2/BCAR1/HOPX/HOXD11/MIR1203/ MYL9/SLC9A3R2/SYT5/VTRNA1-3/HLF	41	39	–/–	Plasma	MeDIP-seq and qPCR	[44]
Diagnosis	DCLK1	65	95	49.2%/91.6%	Plasma	qMSP	[45]
Diagnosis	CDH1/NISCH	40	30	–/–	Plasma	MSP	[46]
Diagnosis	CDO1/HOXA9/AJAP1/PTGDR/UNCX/ MARCH11	83	42	72.1%/71.4%	Serum	MSP and qMSP	[47]
Diagnosis	RTEL1/PCDHGB6	70	80	62.9%/90%	Plasma	qMSP	[48]
Diagnosis	MIR129-2/LINC01158/CCDC181/PRKCB/ TBR1/ZNF781/MARCH11/VWC2/SLC9A3/ HOXA7	18	47	83.0%/95.0%	Plasma	Two-set qPCR	[49]
Prognosis	DCLK1	37	0	–/–	Plasma	qMSP	[45]
Prognosis	BRMS1	122	24	–/–	Plasma	qMSP	[50]
Prognosis	KMT2C	139	60	–/–	Plasma	qMSP	[51]
Prognosis	SOX17	122	49	–/–	Plasma	qMSP	[40]

ISSN: 1868-7083